Number of the records: 1
ustekinumab
SYS d000069549 LBL 00000nz--a2200181n--4500 005 20250606221750.4 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D12.776.124.486.485.114.224.060.937 065 $a D12.776.124.790.651.114.224.060.937 065 $a D12.776.377.715.548.114.224.200.937 066 $a 01 $c 03 150 $a ustekinumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a CNTO 1275 $2 slo 450 $w v $a CNTO-1275 $2 slo 550 $7 sllk_us_auth*d018664 $Y Interleukin-12 $w b $a interleukín-12 550 $7 sllk_us_auth*d053759 $Y Interleukin-23 $w b $a interleukín-23 550 $7 sllk_us_auth*d003879 $Y Dermatologic Agents $w P $a dermatologiká 550 $7 sllk_us_auth*d018664 $Y Interleukin-12 $w p $a interleukín-12 550 $7 sllk_us_auth*d053759 $Y Interleukin-23 $w p $a interleukín-23 665 $a 2016 (2005) $2 eng 680 9-
$i A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies. $2 eng 750 -2
$a Ustekinumab $2 eng 980 $x M
Number of the records: 1